Efficacy of switching from existing anti-vascular endothelial growth factor drugs to ranibizumab biosimilar in neovascular age-related macular degeneration

Efficacy of switching from existing anti-vascular endothelial growth factor drugs to ranibizumab biosimilar in neovascular age-related macular degeneration - Efficacy of ranibizumab biosimilar in neovascular age-related macular degeneration

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000056994

Enrollment

Registered

2025-02-10

Start date

2022-06-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neovascular age-related macular degeneration

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Cases in which nAMD eyes, having remained stable for over a year with treatment using the Treat and Extend (TAE) method with existing anti-VEGF agents (ranibizumab, aflibercept), were switched to ranibizumab biosimilar (BS) based on patient preference.

Exclusion criteria

Exclusion criteria: Patients whose injection intervals were unstable despite treatment with the Treat and Extend (TAE) method using existing anti-VEGF agents, cases with concurrent ocular diseases such as active uveitis or proliferative diabetic retinopathy, cases with a history of vitrectomy or treatments performed at other institutions with insufficient details, and cases in which anterior chamber fluid sampling via anterior chamber paracentesis was deemed unsafe.

Design outcomes

Primary

Measure	Time frame
Visual acuity changes during the observation period	—

Countries

Japan

Contacts

Public ContactHikaru Ota

Nagoya University Hospital Ophthalmology

ota.hikaru.f9@f.mail.nagoya-u.ac.jp052-741-2111

Outcome results